(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
From Iran to Israel: An Iranian volunteer’s unlikely stand in wartime - 2Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential
- 3Flu cases skyrocket in US. See cases, where people got sick.
- 475% of US adults may meet criteria for obesity under new definition, study finds
- 5Merz: 80% of Syrians in Germany should return in three years
- Germany's Lufthansa enters race for stake in Portuguese airline TAP
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- Bad flu season getting worse; skyrocketing cases set state record
- Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital
- The Job of a Land Legal counselor in Property Exchanges
- Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- Zelensky names spy chief to head presidential office after corruption row
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
